Literature DB >> 20345239

Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.

Matthew J Memoli1, Rachel J Hrabal, Arash Hassantoufighi, Maryna C Eichelberger, Jeffery K Taubenberger.   

Abstract

Pandemic 2009 H1N1 virus isolates containing the neuraminidase inhibitor resistance mutation H275Y have been reported. We describe rapid selection for the H275Y resistance mutation during therapy in 2 immunocompromised individuals at 9 and 14 days of therapy, as well as the first described case of clinically significant resistance to peramivir.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20345239      PMCID： PMC2946636          DOI： 10.1086/651605

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


  15 in total

Review 1.  Position statement: global neuraminidase inhibitor susceptibility network.

Authors:  M Zambon; F G Hayden
Journal:  Antiviral Res       Date:  2001-03       Impact factor: 5.970

2.  A novel neuraminidase deletion mutation conferring resistance to oseltamivir in clinical influenza A/H3N2 virus.

Authors:  Yacine Abed; Mariana Baz; Guy Boivin
Journal:  J Infect Dis       Date:  2009-01-15       Impact factor: 5.226

Review 3.  Pandemic and seasonal influenza: therapeutic challenges.

Authors:  Matthew J Memoli; David M Morens; Jeffery K Taubenberger
Journal:  Drug Discov Today       Date:  2008-05-15       Impact factor: 7.851

4.  Rapid selection of a transmissible multidrug-resistant influenza A/H3N2 virus in an immunocompromised host.

Authors:  Matthew J Memoli; Rachel J Hrabal; Arash Hassantoufighi; Brett W Jagger; Zong-Mei Sheng; Maryna C Eichelberger; Jeffery K Taubenberger
Journal:  J Infect Dis       Date:  2010-05-01       Impact factor: 5.226

5.  Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.

Authors:  Vasiliy P Mishin; Frederick G Hayden; Larisa V Gubareva
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

6.  Universal primer set for the full-length amplification of all influenza A viruses.

Authors:  E Hoffmann; J Stech; Y Guan; R G Webster; D R Perez
Journal:  Arch Virol       Date:  2001-12       Impact factor: 2.574

7.  Characterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivir.

Authors:  Mariana Baz; Yacine Abed; Guy Boivin
Journal:  Antiviral Res       Date:  2006-11-20       Impact factor: 5.970

8.  Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child.

Authors:  Mariana Baz; Yacine Abed; Jane McDonald; Guy Boivin
Journal:  Clin Infect Dis       Date:  2006-11-08       Impact factor: 9.079

9.  Oseltamivir-resistant novel influenza A (H1N1) virus infection in two immunosuppressed patients - Seattle, Washington, 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-08-21       Impact factor: 17.586

10.  Update: drug susceptibility of swine-origin influenza A (H1N1) viruses, April 2009.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-05-01       Impact factor: 17.586
View more
  65 in total

1.  Therapeutic activity of intramuscular peramivir in mice infected with a recombinant influenza A/WSN/33 (H1N1) virus containing the H275Y neuraminidase mutation.

Authors:  Yacine Abed; Andrés Pizzorno; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2012-06-04       Impact factor: 5.191

2.  Emerging influenza antiviral resistance threats.

Authors:  Frederick G Hayden; Menno D de Jong
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

3.  Generation and characterization of recombinant pandemic influenza A(H1N1) viruses resistant to neuraminidase inhibitors.

Authors:  Andrés Pizzorno; Xavier Bouhy; Yacine Abed; Guy Boivin
Journal:  J Infect Dis       Date:  2011-01-01       Impact factor: 5.226

4.  Deep sequencing reveals mixed infection with 2009 pandemic influenza A (H1N1) virus strains and the emergence of oseltamivir resistance.

Authors:  Elodie Ghedin; Jennifer Laplante; Jay DePasse; David E Wentworth; Roberto P Santos; Martha L Lepow; Joanne Porter; Kathleen Stellrecht; Xudong Lin; Darwin Operario; Sara Griesemer; Adam Fitch; Rebecca A Halpin; Timothy B Stockwell; David J Spiro; Edward C Holmes; Kirsten St George
Journal:  J Infect Dis       Date:  2011-01-15       Impact factor: 5.226

5.  Deep sequencing of 2009 influenza A/H1N1 virus isolated from volunteer human challenge study participants and natural infections.

Authors:  Yongli Xiao; Jae-Keun Park; Stephanie Williams; Mitchell Ramuta; Adriana Cervantes-Medina; Tyler Bristol; Sarah Smith; Lindsay Czajkowski; Alison Han; John C Kash; Matthew J Memoli; Jeffery K Taubenberger
Journal:  Virology       Date:  2019-06-13       Impact factor: 3.616

6.  Pandemic Influenza A H1N1 (2009) Virus: Lessons from the Past and Implications for the Future.

Authors:  Madhu Khanna; Binod Kumar; Ankit Gupta; Prashant Kumar
Journal:  Indian J Virol       Date:  2012-03-25

7.  ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.

Authors:  J H Beigel
Journal:  Drugs Future       Date:  2010-05       Impact factor: 0.148

Review 8.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

9.  Efficacy of repeated intravenous injection of peramivir against influenza A (H1N1) 2009 virus infection in immunosuppressed mice.

Authors:  Mitsutaka Kitano; Makoto Kodama; Yasushi Itoh; Takushi Kanazu; Masanori Kobayashi; Ryu Yoshida; Akihiko Sato
Journal:  Antimicrob Agents Chemother       Date:  2013-03-11       Impact factor: 5.191

10.  Molecular modeling studies demonstrate key mutations that could affect the ligand recognition by influenza AH1N1 neuraminidase.

Authors:  Gema L Ramírez-Salinas; J García-Machorro; Miguel Quiliano; Mirko Zimic; Verónica Briz; Saul Rojas-Hernández; J Correa-Basurto
Journal:  J Mol Model       Date:  2015-10-26       Impact factor: 1.810
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.